Navigation Links
Raptor Pharmaceuticals Corp. to Present at Two Upcoming Healthcare Conferences
Date:10/28/2008

NOVATO, Calif., Oct. 29 /PRNewswire-FirstCall/ -- Raptor Pharmaceuticals Corp. (OTC Bulletin Board: RPTP), today announced that senior management will present a corporate overview and clinical pipeline updates at two upcoming healthcare investor conferences:

-- The 7th Annual BIO Investor Forum, to be held October 29-31, 2008 at the

Palace Hotel in San Francisco, CA. Raptor's presentation will take

place on Wednesday, October 29 at 4:45pm ET (1:45pm PT) in Telegraph

Hill. A live audio webcast of the presentation will be available at

http://www.corporate-ir.net/ireye/confLobby.zhtml?ticker=RAPTOR&item_id =1996013

-- The Rodman & Renshaw 10th Annual Healthcare Conference, to be held

November 10-12, 2008 at New York Palace Hotel in New York, NY.

Raptor's presentation will take place on Tuesday, November 11 at

9:30am ET (6:30am PT) in Holmes II (4th floor). A live audio webcast of

the presentation will be available at

http://www.wsw.com/webcast/rrshq14/rptp.ob

Both webcasts will be archived for 30 days and accessible through the investor relations section of Raptor's website at http://www.raptorpharma.com.

For more information on BIO Investor Forum conference please visit: http://investorforum.bio.org/opencms/bif/2008/

For more information on Rodman & Renshaw's 10th Annual Healthcare Conference please visit: http://www.rodmanandrenshaw.com/conferences

About Raptor Pharmaceuticals Corp.

Raptor Pharmaceuticals Corp. ("Raptor") is a publicly traded biotechnology company dedicated to speeding the delivery of new treatment options to patients by working to improve existing therapeutics through the application of highly specialized drug targeting platforms and formulation expertise. Raptor focuses on underserved patient populations where it believes it may have the greatest impact. Raptor is involved in clinical development of its proprietary Delayed-Release Cysteamine ("DR Cysteamine") product candidate in nephropathic cystinosis, non-alcoholic steatohepatitis ("NASH"), Huntington's Disease and Batten Disease, and its ConviviaTM product candidate in aldehyde dehydrogenase ("ALDH2") deficiency. In its preclinical programs Raptor bioengineers novel drug candidates and drug-targeting platforms derived from the human receptor-associated protein ("RAP") and related proteins which are designed to target cancer, neurodegenerative disorders and infectious diseases. Raptor's preclinical programs include HepTideTM, WntTideTM and NeuroTransTM.

For additional information, please visit http://www.raptorpharma.com.

FORWARD LOOKING STATEMENTS

This document contains forward-looking statements as that term is defined in the Private Securities Litigation Reform Act of 1995. These statements relate to future events or our future results of operation or future financial performance, including, but not limited to the following statements: Raptor's ability to develop any of its preclinical and clinical drug product candidates. These statements are only predictions and involve known and unknown risks, uncertainties and other factors, which may cause our actual results to be materially different from these forward-looking statements. Factors which may significantly change or prevent our forward looking statements from fruition include that we may be unsuccessful in developing any products or acquiring products; that our technology may not be validated as we progress further and our methods may not be accepted by the scientific community; that we are unable to retain or attract key employees whose knowledge is essential to the development of our products; that unforeseen scientific difficulties develop with our process; that our patents are not sufficient to protect essential aspects of our technology; that competitors may invent better technology; that our products may not work as well as hoped or worse, that our products may harm recipients; and that we may not be able to raise sufficient funds for development or working capital when we require it. As well, our products may never develop into useful products and even if they do, they may not be approved for sale to the public. We caution readers not to place undue reliance on any such forward-looking statements, which speak only as of the date they were made. Certain of these risks, uncertainties, and other factors are described in greater detail in our filings from time to time with the Securities and Exchange Commission (the "SEC"), which we strongly urge you to read and consider, including our Registration Statement on Form S-1 that was declared effective on August 7, 2008; our annual report on Form 10-KSB filed with the SEC on November 14, 2007; and our Form 10-QSB filed with the SEC on July 9, 2008, all of which are available free of charge on the SEC's web site at http://www.sec.gov. Subsequent written and oral forward-looking statements attributable to us or to persons acting on our behalf are expressly qualified in their entirety by the cautionary statements set forth in our reports filed with the SEC. We expressly disclaim any intent or obligation to update any forward-looking statements.

For more information, please contact:

The Ruth Group

Sara Ephraim (investors)

(646) 536-7002

sephraim@theruthgroup.com

Janine McCargo (media)

(646) 536-7033

jmccargo@theruthgroup.com


'/>"/>
SOURCE Raptor Pharmaceuticals Corp.
Copyright©2008 PR Newswire.
All rights reserved

Related medicine news :

1. Glendale Raptors Join Four Points by Sheraton Denver Southeast and Animal Planets Dr. Kevin Fitzgerald for Second Annual Halloween Costume Drive & Halloween Party for Kunsberg School at National Jewish Medical and Research Center
2. The Glendale Raptors Set Dates for Youth Rugby League and USA Rugby Youth Academy
3. Smith & Nephew Endoscopys BIORAPTOR(TM) 2.3 PK Suture Anchor Provides Secure Repair for Shoulder, Hip Instability
4. Vista Partners Updates Coverage on Raptor Pharmaceuticals Corp.
5. Vista Partners Initiates Coverage on Raptor Pharmaceuticals Corp.
6. Anadys Pharmaceuticals Commences Dosing ANA598 in Hepatitis C Patients in Phase Ib Study
7. Idenix Pharmaceuticals to Present at Two Upcoming Investor Conferences
8. Alexion Pharmaceuticals Chooses Blue Mountain Regulatory Asset Manager(R) for Best-in-class Calibration Management Integrated with SAP(R)
9. Perrigo Company Licenses Prescription Brands to Medimetriks Pharmaceuticals
10. CoLucid Pharmaceuticals Names Linda Hogan VP of Business Development
11. Anadys Pharmaceuticals to Present at Bio Investor Forum
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:4/28/2016)... ... April 28, 2016 , ... ... of a new CDISC standard, Clinical Trial Registry (CTR) XML. Clinical trial ... standard will make it possible to build applications that generate submissions for ...
(Date:4/28/2016)... (PRWEB) , ... April 28, 2016 , ... ... and the Campaign for Tobacco-Free Kids, a leading force in the fight to ... federal, state and local policies that can help reduce tobacco use. The initiative ...
(Date:4/28/2016)... ... 2016 , ... In 2011, TIME magazine named Herr the “Leader of the ... that marries human physiology with electromechanics. He continues that work as Director of the ... BionX , a leader in the field of prosthetic devices. , After a ...
(Date:4/28/2016)... ... April 28, 2016 , ... Cognizin® Citicoline ... 2016. , Nominated in the Healthy Ageing category, Cognizin® is being considered for ... Healthy Ageing division can include everything from antioxidants, lipids, proteins, and botanicals. NutraIngredients ...
(Date:4/28/2016)... ... , ... USA Medical Card reminds us that May is National Stroke Awareness Month. According ... cause of death in the United States; someone has one every 40 seconds. Annually, ... under 65 years old. A stroke is when blood flow to the brain is ...
Breaking Medicine News(10 mins):
(Date:4/27/2016)... DELHI , April 27, 2016 ... CSR initiative to save newborns   ... hospital for women & newborns in collaboration with Breast Milk ... launched the first Pasteurized Human Milk Bank, ,Amaara, in Delhi-NCR ... best nutritional food source for infants and should be available ...
(Date:4/27/2016)... Shire plc (LSE: SHP, NASDAQ: SHPG ... will present at the Deutsche Bank 41st Annual Health Care ... May 04, 2016, 10:00 am EDT (15:00 BST). ... and Webcasts section of Shire,s Investor website at http://investors.shire.com/presentations-and-webcasts/ ... on this same website for approximately 90 days. ...
(Date:4/27/2016)... April 27, 2016 Oasmia ... developer of a new generation of drugs within ... survival results for Paclical/Apealea in the Phase III ... with epithelial ovarian cancer. These preliminary results showed ... combination with carboplatin versus Taxol in combination with ...
Breaking Medicine Technology: